Skip to main content
Advertisement
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

January 19, 2023

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

In a modelling study, Dr. Allison Portnoy and colleagues explore the cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries.

Image credit: CDC, Unsplash

PLOS Medicine is experiencing high submission volumes.

Processing of new submissions will restart in January 2023 as new staff are onboarded. We apologise for the delay.

Get new content from PLOS Medicine in your inbox

Thank you! You have successfully subscribed to the PLOS Medicine newsletter.

Sorry, an error occurred while sending your subscription. Please try again later.

Try again
PLOS Medicine | ISSN: 1549-1676 (online)